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Finding gene associations in rare diseases is frequently hampered by the reduced numbers of patients accessible.
Conventional gene-based association tests rely on the availability of large cohorts, which constitutes a serious
limitation for its application in this scenario. To overcome this problem we have used here a combined strategy in
which a pathway-based analysis (PBA) has been initially conducted to prioritize candidate genes in a Spanish
cohort of 53 trios of short-segment Hirschsprung’s disease. Candidate genes have been further validated in an
independent population of 106 trios. The study revealed a strong association of 11 gene ontology (GO) modules
related to signal transduction and its regulation, enteric nervous system (ENS) formation and other HSCR-related
processes. Among the preselected candidates, a total of 4 loci, RASGEF1A, IQGAP2, DLC1 and CHRNA7, related to
signal transduction and migration processes, were found to be significantly associated to HSCR. Network analysis
also confirms their involvement in the network of already known disease genes. This approach, based on the study of
functionally-related gene sets, requires of lower sample sizes and opens new opportunities for the study of rare diseases.
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Understanding complex genetic diseases is one of the
great challenges for XXIst century medicine. In the past
few years, the development of new tools, such as
Genome-Wide Association Studies (GWAS) and Next
Generation Sequencing (NGS), has allowed the identifica-
tion of hundreds of genetic variants associated to different
diseases that provide new insights of their genetic archi-
tecture. Hirschsprung’s disease (HSCR, OMIM 142623) is
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distribution, and reproduction in any mediumcomplex genetic diseases. HSCR or aganglionic megacolon
is a rare developmental disorder of variable penetrance
and expressivity, male predominance, and an incidence of
1/5000 newborn human infants. It is a neurocrystopathy
characterized by the absence of intramural ganglion cells
in the myenteric and submucosal plexuses along a variable
portion of the distal intestine. The most widely accepted
etiopathogenetic hypothesis for HSCR is based on a defect
of craniocaudal migration of neuroblasts originating from
the neural crest that, under normal circumstances, reach
the small intestine in the 7th week of gestation and the
rectum in the 12th week [1].
The HSCR clinical forms with variable extension of
the aganglionic segment could be interpreted as inter-
ruptions of the migration process in different gestational
periods: the earlier the migration arrest, the longer the
distal aganglionic intestinal portion. Based on the length
of the aganglionic region, the disorder is classified intotral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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sigmoid colon, 80% of cases), long-segment (L-HSCR:
aganglionosis up to the splenic flexure and beyond, 17%
of cases) and total colonic aganglionosis forms (TCA,
3% of cases). Significantly, HSCR displays a highly vari-
able phenotype with variation in recurrence risk by gen-
der, familiarity, segment length of aganglionosis and
associated phenotypes [2]. The reason for most of this
variation is largely unknown, although gene discovery
has clarified some genotype-phenotype correlations.
Numerous molecular genetic studies have identified rare
coding mutations in many genes (RET, GDNF, NRTN,
PSPN, GFRA1, EDNRB, EDN3, ECE1, NTF3, NTRK3,
SOX10, PHOX2B, L1CAM, ZFHX1B, KIAA1279, TCF4,
PROK1, PROKR1, PROKR2, NRG1, SEMA3A and
SEMA3D) related to HSCR [1-8]. Moreover, several add-
itional HSCR-associated regions, such as 9q31 [9], 3p21
[10,11], 19q12 [10], 16q23 [12], 21q21 [13] or 4q31.3-
q32.3 [14] have been described, although the genes
underlying such associations have not been identified
yet. However, cumulatively, the conventional mutations
related to HSCR reported so far explain around 5% of
cases, being the vast majority of them L-HSCR/TCA
and syndromic forms of the disease [1,2]. Additional
phenotypic variation is explained by common low-
penetrance polymorphic variants at RET (10q11.21)
[2,15,16] and NRG1 [17], but the vast majority of HSCR
heritability is still unknown. In other words, all these
genes and loci seem to contribute to HSCR phenotype,
but associations change according to the population
studied and the way of contribution of the different ele-
ments is still unclear.
Conventional GWAS, based on single markers, require
of large cohorts. This represents an especially remark-
able limitation for the case of rare diseases, where typic-
ally a limited number of patients are available. In an
attempt to overcome this limitation, pathway-based ana-
lysis (PBA) [18] has been applied to select groups of
functionally-related genes collectively associated to the
disease (through their corresponding SNPs) in a first
analysis step. Actually, PBA has already been successfully
applied to the study of several diseases [19-21]. The ap-
plication of PBA tests produced a reduced list of candi-
date genes which was further validated with an
independent set of SNPs in a larger population of 106
trios. The result of this validation was the identification
of four new loci associated to the disease, RASGEF1A,
IQGAP2, DLC1 and CHRNA7, accounting for different
defects in biological processes related to HSCR, such as
signal transduction (particularly the Ras pathway) and
ENS formation. In addition, network analysis was used
as supplementary evidence to support the results found.
Network analysis, exploits the information contained in
the interactome with the idea that proteins close in theinteraction network will have a higher probability of
causing the same disease and constitutes a powerful
technique to detect gene-disease associations [22-24].
Network analysis has been successfully applied to dis-
cover genes in different diseases, such as ataxias [25],
Huntington disease [26], schizophrenia [27] or Alzhei-
mer’s disease [28].
Material and methods
Subjects
We have included in this study a total of 159 sporadic
isolated HSCR trios, composed by the affected patients
(127 males, 32 females) and their unaffected parents, all
of them originating from Spain. A total of 103 out of the
159 patients were S-HSCR, 31 presented with L-HSCR
and the length of aganglionosis was not available for the
remaining 25 cases.
For the first part of this study, consisting in the gen-
ome wide genotyping study, we selected 53 S-HSCR
trios. For further validation studies of the candidate
genes resulting from GWAS, we genotyped an inde-
pendent selection of SNPs in an independent series of
106 trios.
An informed consent was obtained from all the parti-
cipants for clinical and molecular genetic studies. The
study conformed to the tenets of the declaration of Hel-
sinki as well as the requirements established by our In-
stitutional Review Board.
Genome-wide genotyping
Genome wide genotyping was carried out using the
Affymetrix 500 k chip (composed of the 250 k Nsp and
the 250 k Sty chips) and the GenechipW System (Affyme-
trix). Quality controls were as follows: SNPs missing in
more than 20% of the samples in the calling process
were discarded. SNPs with MAF < 0.5%, with Mendelian
errors or not in Hardy-Weinberg equilibrium (in un-
affected samples; p-value < 10-5) were also discarded.
Samples with more than 5% of the SNPs missing were
not considered for further analysis. Data are available in
the Gene Expression Omnibus (GEO) database (http://
ncbi.nlm.nih.gov/geo/) under the identifier GSE33732.
Conventional gene association analysis in trios
Transmission Disequilibrium Test (TDT) association
statistics was carried out as implemented in the PLINK
[29] software for the 53 trios included in the genome
wide genotyping.
Pathway-based analysis
The SNPs were ranked according to their p-values
obtained in the TDT test and a PBA test [30], as imple-
mented in the GESBAP [31] module of the Babelomics
software [32,33], was conducted. Briefly, PBA tests make
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borhood (here defined as 500 bps up-and downstream of
the gene limits). When multiple SNPs map onto the
same gene, the SNP with lowest (most significant)
p-value is retained. In this way, a list of genes ranked by
the p-values of the SNPs mapping onto them is con-
structed. Then the PBA test analyzes the distribution of
sets of functionally related genes across the list. Here we
use Gene Ontology (GO) [34] terms to define the func-
tional modules tested. GO terms significantly associated
to low p-values are found upon the application of a lo-
gistic regression. To avoid false positives due to
multiple-testing effects, only GO terms with a FDR-
adjusted [35] p-value < 0.05 are declared significant.
PBA-based two stage study
A widely used strategy involves the genotyping of a
number of samples for a large number of markers on a
first stage (discovery step), followed by a second geno-
typing step of a smaller selection of markers in another
(larger if possible) subset of samples (validation step).
The standard approach considers stage 2 as a replication
study and focus on markers statistically significant when
stage 2 is considered alone [36].
Here, instead of using a conventional approach based on
single marker associations for the discovery step, we have
followed a conceptually different approach. Our approach
is inspired in an idea that is gaining popularity, that a dis-
ease is rarely the consequence of a defect in a single gene,
but rather reflects the perturbations of the complex net-
work of functionally related gene modules [23,37,38].
Therefore, we have used PBA to discover gene modules
(represented by GO terms) significantly associated to the
disease. Then, we consider that genes belonging to such
GO modules define a subset of candidate genes to be
tested in the second stage. A similar idea has already suc-
cessfully been used for gene expression analysis [39].
According to the PBA carried out in the discovery
stage, a total of 68 candidate genes belonging to the GO
modules most associated to the disease were selected be-
cause of their lower p-values. A total of 190 new SNPs
mapping onto the 68 candidate genes (an average of 1–3
SNP/gene) were subsequently selected for further evalu-
ation. Selection of SNPs within those genes followed 4
main criteria: they were not included in the chip used
for the first genotyping study, they should be homoge-
neously distributed along the entire sequence of the gene
(including regions susceptible of being regulatory ele-
ments), their reported allelic frequency should be of at
least 5% in Caucasian population and should have been
identified as Tag SNPs by the HapMap Project. The soft-
ware PupaSuite [40] was used to help in this section. Large-
scale validation genotyping of each SNP was performed in
the independent series of 106 trios by Taqman technologyusing 7900HT Fast Real-Time PCR System (Applied Bio-
systems, Foster City, California, USA) as previously
described. As usual, significance in the transmission of the
alleles in the families is tested by an X2 test, applying aYates
correction (SPSS v.17.0).
One limitation of this approach is that SNPs not map-
ping within (or close) to genomic elements with a func-
tional annotation will be missed. However, the power for
detection of associations of SNPs related to genes with
some known function, interaction, etc., is greatly increased
by this approach.
Expression analyses
Human postnatal gut specimens were obtained from
endoscopic gut samples biopsied from patients in the
University Hospital Virgen del Rocío because of different
medical indications. Except for the case of RASGEF1A,
whose expression had already been verified in ENS [16],
these samples were used to verify gene expression of the
genes that resulted associated to HSCR, by both RT-
PCR and immunohistochemistry analyses.
The cDNA specimens from those tissue samples were
obtained with the gentleMACS™ Dissociator and ther-
moMACS™ Separator systems (Miltenyi Biotech) follow-
ing the protocols recommended by the manufacturers.
RT-PCR analyses were performed on such cDNA sam-
ples to test expression of each of the associated genes.
As positive controls we used Brain Human Normal
cDNA, Kidney Human Normal cDNA and Liver Human
Normal cDNA (Invitrogen). Primer sequences and con-
ditions are available on request.
Paraffin gut tissue sections (normal and HSCR gut,
pancreas, cerebral cortex, testis and lung; 5 μm thick)
were dewaxed in xylene and rehydrated in a series of
graded alcohols. Endogenous peroxidase activity was
blocked with water containing 3% H2O2 for 30 minutes.
Antigen retrieval was done by microwaving using citrate
phosphate buffer (pH 6.0). Sections were incubated at
4°C overnight with the primary antibodies: IQGAP2
(1:10.000 dilution, mouse monoclonal, Santa Cruz Bio-
technology), CHRNA7 (1:5000 dilution, rabbit poly-
clonal, Sigma Aldrich) and DLC1 (1:2000 dilution, rabbit
polyclonal, Sigma Aldrich). After several washes in Tris
buffer, peroxidase-labeled secondary antibodies and 3,3'-
diaminobenzidine were applied to develop immunoreac-
tivity, according to manufacturer’s protocol (EnVision;
Dako, Glostrup, Denmark). The slides were then coun-
terstained with hematoxylin and mounted in DPX (BDH
Laboratories, Poole, UK). Sections of cerebral cortex and
lung were used as negative controls, while sections of
pancreas and testis were used as positive controls to test
the three primary antibodies. Photographs were taken
at 20 um and 50 um the microscope BX61 (Olympus)
with a digital camera DP72 and captured through the
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sues except gut) were selected according the webpage:
http://www.proteinatlas.org/.
Network analysis
The information on protein interactions that define the
so called interactome provides an independent view on
the biological consistence of the relationship of a set of
genes with a disease [41,42]. Here, we have studied the
connectivity of the genes discovered in our analysis to
the genes already known to be associated to HSCR by
means of the program SNOW [43], implemented in the
Babelomics package [33]. SNOW detects the largest
sub-network linking all these genes and tests if some
network parameters are significantly beyond their corre-
sponding random expectations. An extended version of
the interactome that includes protein interactions
described in Reactome has been used here [44].
An empirical distribution of the random expectation
of the parameters of a network of N components can be
obtained by repeatedly sampling random sets of N genes
from the complete genome and calculating the average
parameters of their corresponding minimum connecting
trees. Thus, the parameters obtained for the network to
be tested can be contrasted with respect to their corre-
sponding random expectations [43].
Results
Pathway-based analysis
The whole workflow-type overview of the steps carried
out in this project is reflected in the Additional file 1:
Figure S1. Only the RET gene was found as significantly
associated to HSCR (FDR-adjusted p-value = 7.39x10-3)
upon the application of a conventional SNP-based TDT
on the data resulting from the GWAS in the 53 HSCR
trios. Figure 1 contains a graphical representation the
distribution of p-values obtained from the TDT.
Then, we conducted the PBA test, as implemented in
the Babelomics package, over the list of markers ranked byFigure 1 Graphical summary of the genome wide TDT on the first po
represents the chromosome position in the consecutive, color-coded chromp-value (see Materials and Methods). In this discovery step,
we found a total of 11 GO modules significantly associated
to HSCR, with FDR-adjusted p-values < 0.01. Five of them
were related to signal transduction and its regulation: Ras
protein signal transduction (GO:0007265), regulation of Ras
protein signal transduction (GO:0046578), regulation of
small GTPase mediated signal (GO:0051056), regulation of
Rho protein signal transduction (GO:0035023) and small
GTPase mediated signal transduction (GO:0007264). With
lower significance, although still significant at FDR-adjusted
p-values < 0.05, and belonging to the same GO branch
and descendants of the term signal transduction, the GO
terms enzyme linked receptor protein signaling pathway
(GO:0007167) and regulation of signal transduction
(GO:0009966) can also be considered as associated to the
disease (see Table 1 and Figure 2). The Ras pathway is a
well known intracellular signalling pathway, mediated by
the RET receptor and involved in cell survival and prolif-
eration. Both processes are essential in ENS formation [45].
In addition, previous studies have demonstrated that signal-
ling through the small Rho GTPases is also important for
colonization of the gut by enteric neural crest cells (ENCC)
and the concomitant growth of axons [45]. These results
strongly suggest that members of the Ras/Rho protein sig-
nal transduction or regulators are most probably playing a
key role in the pathogenesis of HSCR, as particularly sup-
ported by the association of the GO modules above men-
tioned, descendant in the GO hierarchy of the small
GTPase mediated signal transduction term (Figure 2).
On the other hand, migration of ENCC in the gut wall
during embryogenesis requires interactions between the
migrating neural crest cells and the extracellular matrix
environment in different regions of the developing gut.
Therefore, it results evident the key role of cell-cell
adhesion (GO:0016337), with a marginal, but still signifi-
cant (FDR-adjusted p-value < 0.05) association to the dis-
ease, during ENS system formation. It is not surprising
that genes belonging to this functional module are
involved in HSCR. Our analysis also reveals otherpulation of 53 trios used as stage 1 association. The x axis
osomes and the y axis shows -log10[p-value]. See details in the text.
Table 1 GO modules significantly associated to HSCR (FDR-adjusted p–values < 0.01)
GO ID Definition Significance
(Adj. p-val < 0.05)
GO:0051056 regulation of small GTPase mediated signal transduction 3.216x10-5
GO:0046578 regulation of Ras protein signal transduction 6.825x10-5
GO:0007268 synaptic transmission 4.259 x10-4
GO:0007265 Ras protein signal transduction 8.245 x10-4
GO:0007264 small GTPase mediated signal transduction 3.136 x10-3
GO:0035023 regulation of Rho protein signal transduction 5.369 x10-3
GO:0006816 calcium ion transport 6.978 x10-3
GO:0016337 cell-cell adhesion 0.01203
GO:0006812 cation transport 0.02391
GO:0007167 enzyme linked receptor protein signaling pathway 0.03174
GO:0009966 regulation of signal transduction 0.04825
Values in italics are marginally significant at FDR-adjusted p-values < 0.05.
Figure 2 Hierarchy of GO terms significantly associated to HSCR in the trios analyzed. GO terms with a highly significant association to the
disease (p-value < 10-3) to the disease are labeled in red; GO terms with higher, but still significant p-values (between 0.01 and 0.05), that are
related to the highly significant GO terms in the GO hierarchy are labeled in blue.
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calcium ion transport (GO:0006816) and, marginally,
cation transport (GO:0006812), whose biological signifi-
cance in the context of ENS formation is evidenced by
the key role of ionic transport processes in cell migration
context. A migrating cell has to govern cell volume regu-
latory ion transport mechanisms in order to create the
appropriate micro- or even nano-environment in the
intra- and/or extracellular space, which is necessary to
guarantee the correct polarity and hence direction of
movement of a migrating cell. Therefore, these asso-
ciated GOs might provide potential candidate genes to
be involved in ENS formation and also the pathogenesis
of HSCR.
Validation of candidate genes
As previously mentioned, a conventional marker-based
test rendered only a gene association to the disease,
which was, as expected, the RET proto-oncogene. Ex-
cluding this gene, whose association with the disease has
been already extensively reported, we selected a series of
68 additional genes represented in those HSCR-
associated GO modules, in order to validate and analyze
in more depth the previous functional association
results. These 68 genes were those with highest nominal
p-values in SNPs mapping onto them. Among those 68
genes, a selection of 190 SNPs was also done (2–3 per
gene) and we tested their distribution in the whole series
of trios (Additional file 2: Table S1). Genotyping of the
selected variants was performed by Taqman technology
and their distribution was compared between transmit-
ted and untransmitted alleles from unaffected parents to
their affected offspring. This analysis revealed a signifi-
cant association of 4 out of the 68 genes analyzed, as
shown in Table 2. Noteworthy, 2 genes, DLC1 and RAS-
GEF1A, presented association to HSCR with 2 and 3
SNPs respectively, while for the remaining genes only 1
of the tested SNPs resulted in statistical significance. A
detailed inspection of the associated genes in the context
of the GO modules, showed that 3 of them are part of
the signal transduction related terms (RASGEF1A,
IQGAP2, DLC1) and the other one is part of GOs related
to migration processes (CHRNA7) (Table 2).
In addition, the expression of the 4 genes in human
gut specimens was verified by both immunohistochem-
ical (Figure 3) and RT-PCR (Figure 4) analyses.
Confirmatory network analysis
In order to find additional independent evidences on the
biological reliability of the genes validated, we have ap-
plied network analysis [41] to look for significant net-
works that link the discovered genes to already known
disease genes. Thus, we applied the network significance
test implemented in the SNOW program, which is nowpart of the Babelomics suite, to the 4 discovered genes
and the genes already known to be related to HSCR by
numerous studies [1-8]. Figure 5 shows a network that
links a group of 12 disease genes and 3 of the 4 vali-
dated. This is a considerable number of genes participat-
ing in the network even though that there is only
information on protein interactions for 11 out of the
genes previously related to HSCR, and for 3 out of 4
new genes here identified. This network displays a
betweenness value which is significantly higher that the
random expectation (p-value = 0.01). This parameter
accounts for the number of shortest pathways that con-
nect any two proteins in the sub-network passing
through a given node and is an average value. Despite
the biological interpretation of network parameters is
not always obvious, a high betweenness is characteristic
of signaling pathways, which is consistent with the find-
ings based on the GO terms. Both types of evidences
point towards processes related to signaling associated
to HSCR.
Obviously only genes for which information on the
interaction of their gene products is available were used
in the derivation of the network. This means that the
networks found are most probably an underestimation
of the real network associated to the disease.
Discussion
High-throughput genomic technologies are revolutioniz-
ing biology and medicine by providing more and more
resolution in the data produced. However, at the same
time, are posing new challenges in the way such data
can be analyzed and interpreted. In particular, conven-
tional marker-based analysis of GWAS requires of large
sample sizes to find significant associations given that
some genes may be really associated with the disease,
but may not reach a stringent genome-wide significance
threshold required in a massive multiple testing scenario
[18]. This makes of GWAS a methodology especially im-
practicable in the field of rare diseases. In order to over-
come the limitations of conventional single-marker
based association analysis, alternative approaches for
the analysis of GWAS analysis have been proposed in
the last few years. Beyond testing solutions that use mul-
tiple markers or marker information, such as linkage,
etc., the recent proposal of PBA approaches has intro-
duced a new angle in the analysis of GWAS data, closer
to the principles of systems biology. Typically, PBA
approaches check whether some statistics have consist-
ent yet moderate deviation from chance for a group of
related genes (for example, belonging to a GO category).
The rationale for this approach is the accepted notion
that genes do not work in an isolated way, but rather
in complex molecular networks and cellular pathways
that are often involved in disease susceptibility and
Table 2 Validation of the genes in the stage II, independent population of 106 trios
Gene SNP Allele Transmited Untransmited Statistic and p-value
RASGEF1A (rs1254964 p = 3.856x10-05) rs1254958 G 143 (67.45%) 187 (88.2%) χ 2 = 25.27; p = 5x10-7
A 69 (35.55%) 25 (11.8%)
rs10793422 G 141 (66.5%) 184 (86.8%) χ 2 = 23.25; p = 1.4 x10-6
A 71 (33.5%) 28 (13.2%)
rs2503846 T 32 (15.0%) 71 (33.5%) χ 2 = 18.52; p = 1.68x10-5
G 180 (85.0%) 141 (66.5%)
IQGAP2 (rs950643 p = 0.0003585) rs3797412 A 146 (68.8%) 179 (84.4%) χ 2 = 13.49; p = 2.393x10-4
G 66 (31.2%) 33 (15.6%)
DLC1 (rs1454947 p = 0.007526) rs9325866 T 34 (16.0%) 52 (24.5%) χ 2 = 4.22; p = 0.0401
C 178 (8.04%) 160 (75.5%)
rs536147 T 36 (16.9%) 56 (24.5%) χ2 = 5.00; p = 0.0252
C 176 (83.1%) 156 (75.5%)
CHRNA7 (rs2175886 p = 0.000607) rs868437 C 47 (22.2%) 76 (35.8%) χ 2 = 8.98; p = 0.0027
T 165 (77.8%) 136 (64.2%)
Genes are shown along with the best scoring SNPs mapping onto them and the corresponding p-values obtained in the stage I. See text for details.
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logical knowledge about relationships among genes and
pathways will increase the possibility of identifying the
genes and mechanisms that are involved in disease
pathogenesis [48]. Here we have adopted a widely
accepted definition of gene functionality, which is repre-
sented by the GO. One obvious limitation of this ap-
proach is that variants not mapping within, or close to,
genomic elements with a functional annotation will be
missed. However, it is known that coding genes and
functional elements in their neighborhood (e.g. splice ac-
ceptor and donor sites, transcription factor binding sites,
etc.) harbor 85% of the mutations with large disease
related effects [49,50].
In this study we have applied a new approach which
can be considered a functional version of a two stage
analysis of GWAS data. In our approach, the conven-
tional discovery stage based on markers is substituted by
a PBA, that allows us to identify biological processes
(represented by GO terms) associated to the disease in
the Spanish population. The subsequent step of valid-
ation allowed us to identify 4 new gene associations to
the disease among the ones belonging to the associated
GO categories.
It is believed that aganglionosis that characterizes
Hirschsprung can arise from: (1) reduced size of the
stem/progenitor cell pool; (2) loss of stem cell potency
leading to premature differentiation of progenitors; (3)
reduced cell survival/ increased cell death; (4) intrinsic,
cell-autonomous migration defect of the ENCC; (5)
abnormal gut microenvironment; and (6) abnormal
interaction of enteric neural crest cells with the gut
microenvironment. However, factors that affect the
ENCC motility/proliferation/differentiation, and thusprobably implicated in HSCR, are not clearly known, as
are not how the intrinsic cell migration ability or the
NCC-gut microenvironment interaction is controlled at
the cellular and molecular level. The PBA here con-
ducted on affected patients, not only confirms the most
accepted theory for the biological processes implicated
in HSCR, but also provides an important initial hypoth-
esis to select candidate genes for further evaluation in
the context of the disease. In this sense, and to reinforce
the power of the proposed approach, a significant associ-
ation to the disease could be confirmed for 4 genes after
the evaluation of 68 candidate genes chosen on the basis
of their inclusion in the GOs associated to the disease.
Moreover, expression of those genes was demonstrated
through RT-PCR and immunohistochemistry analyses in
human postnatal gut tissue, obtained from patients with
different clinical conditions. Today is widely accepted
that neurogenesis takes place in human postnatal ENS, a
process which mimics the embryonic events during the
formation of the ENS. Due to the limitations of working
with human embryonic gut tissue, a postnatal gut con-
text is a powerful tool to identify new genes implicated
in the development of ENS, and therefore our results
would support again the implication of the tested genes
in Hirschsprung disease.
In fact, some of the validated genes had been already
related to HSCR either directly or indirectly. That is the
case of RASGEF1A gene, whose 3 SNPs selected for val-
idation resulted to be all significantly over-transmitted
to affected patients. This is not surprising, since RAS-
GEF1A is located around 65.5 Kb upstream RET, and
previous TDT studies had already showed statistically
significant disease associations spanning a region imme-
diately 50 of RET through to this gene [16] reflecting the
Figure 3 Expression analysis by immunohistochemistry of IQGAP2 (A-D), CHRNA7 (E-H) and DLC1 (I-L) in human tissues: normal gut
(A, E, I), HSCR gut (B, F, J), lung (C, G), pancreas (D), testis (H, L) and cerebral cortex (K). Both normal and HSCR guts represent myenteric
plexuses. Scale bars: 20 μm.
Figure 4 Expression analysis by RT-PCR of IQGAP2 (A), CHRNA7 (B) and DLC1 (C) in human gut tissues. cDNAs of kidney, brain and liver
have been used as positive controls for RT-PCR. PCR of B-actin was performed with the different cDNAs used in the study (D).
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Figure 5 Sub-network that links disease genes to the new, validated genes found in this work by the application of the program
SNOW (see Materials and Methods). Disease genes are represented as blue ovals, validated genes are represented as green circles and related
connecting included by the network analysis procedure are represented with squares.
Fernández et al. Orphanet Journal of Rare Diseases 2012, 7:103 Page 9 of 12
http://www.ojrd.com/content/7/1/103high background linkage disequilibrium in this region.
RasGEF1A acts as very specific guanine nucleotide ex-
change factor for Rap2, a member of the Rap subfamily
of Ras-like G-proteins implicated in the regulation of
cell adhesion, the establishment of cell morphology, and
the modulation of synapses in neurons [51]. Although
association tests have excluded the occurrence of a com-
mon mutation at RASGEF1A in HSCR, the possibility
remains that this gene might carry relevant rare muta-
tions related to HSCR. Importantly, RASGEF1A has been
reported to be highly expressed in early embryonic de-
velopment, at a stage coincident with peak RET expres-
sion and colonization of the gut by neural crest-derived
neuronal precursors, which would fit with a potential
role in enteric neural crest migration [16]. Regarding
CHRNA7, it encodes a nicotinic acetylcholine receptor
implicated in synaptic transmission regulated by NRG1
among others [52]. Very interestingly, NRG1 has been
associated to the disease through both common [17,53]
and rare variants [6,54]. In addition, NRG1 SNPs canmodulate significantly CHRNA7 expression [52] and for
this reason it would be necessary to evaluate the possi-
bility that NRG1 SNPs associated to HSCR act in com-
bination with CHRNA7 leading to a susceptibility for the
manifestation of HSCR phenotype.
On the other hand, the remaining significant genes
have major functions in early embryogenesis or ENS de-
velopment, which makes conceivable that, although not
previously related to HSCR, they might play a role in its
pathogenesis. DLC1 is essential for embryonic develop-
ment affecting to neural tube development [55] modu-
lating the cytoskeleton and producing morphological
changes [56]. IQGAP2 function is still unclear, although
studies in with morpholinos X. laevis showed that it reg-
ulates cell-cell adhesion during early development
[57,58]. According to the network analysis, IQGAP2 is
strongly connected to DLC1 through five simultaneous
connections mediated by the genes RAC1, RAC2, RAC3,
RHOG and CDC42. It is also connected to GDNF
(already associated to HSCR) through the NFKB1 gene.
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mental evidences of protein interactions firmly link
IQGAP2 to the disease.
In addition valuable information has been also obtained
from the network analysis, since it has let us to link the
newly identified genes to ones already known to be
involved in Hirschsprung. This supports of the associa-
tions found and reinforces the role of the new genes in
the disease, even though when real network associated to
Hirschsprung is probably underestimated because of the
lack of information on some gene interactions.
In summary, here we report a number of new candi-
date genes for HSCR. They need further investigation to
elucidate their role in the disease and must be also vali-
dated in other populations to discern if their effect in
HSCR is universal or is restricted to the Spanish popula-
tion. Nevertheless, our most important conclusion is
that this comprehensive profile of GO terms has demon-
strated to be a useful resource for developmental, bio-
chemical and genetic studies. Our report indicate that
this approach can help to identify candidate genes for
human disease susceptibility loci. These findings could
be of especial importance in the field of rare diseases,
where large cohorts are often unavailable. In that sce-
nario, the lower sample size requirements make of this
approach a suitable and efficient alternative to marker-
based analyses.
Beyond technical considerations on the advantages of
using GO modules in the analysis of genotype data, the
biological pathways highlighted by our study provide
insights into the complex nature of HSCR, opens new
opportunities for validation of new disease genes and
may help in the definition of relatively tractable targets
for therapeutic intervention.
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